Latest news with #EnovisCorporation
Yahoo
5 days ago
- Business
- Yahoo
UBS Lowers PT on Enovis Corporation (ENOV) to $57 From $65, Keeps a Buy Rating
Enovis Corporation (NYSE:ENOV) is one of the . On August 8, UBS lowered the firm's price target on Enovis Corporation (NYSE:ENOV) to $57 from $65, keeping a Buy rating on the shares. A patient recieving cold therapy treatment using the company's products. The rating update came after Enovis Corporation (NYSE:ENOV) reported fiscal Q2 2025 earnings on August 7, with net sales for the quarter reaching $565 million, reflecting a 7% growth on a reported basis and 5% on an organic basis compared to the same quarter last year. Management reported that fiscal Q2 results reflect stable end markets, continued execution in P&R and Recon, and positive momentum in new product introductions. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16-07-2025
- Business
- Yahoo
Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT
Enovis Corporation (NYSE:ENOV) is one of the best undervalued medical device stocks to buy now. In a report released on July 8, Vijay Kumar from Evercore ISI maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $46.00. A patient recieving cold therapy treatment using the company's products. The company reported continued commercial momentum in fiscal Q1 2025 results, with net sales for the quarter reaching $559 million and reported an 8% growth on a reported basis and 9% rise on a comparable basis from the same quarter last year. Reconstructive sales for the quarter rose 11% year-over-year on a reported basis. Enovis Corporation's (NYSE:ENOV) fiscal Q1 2025 results show a rebound in growth in Recon, net sales for which grew 11% on a reported and comparable basis. The company also showed accelerating momentum in new product introductions and continued execution in P&R, reflecting a 5% growth on a reported basis and 7% on a comparable growth basis. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
24-06-2025
- Business
- Yahoo
Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT
Enovis Corporation (NYSE:ENOV) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 28, Jefferies analyst Young Li maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $60.00. The positive rating was based on several key factors, as the company reported a strong start to the year with notable growth figures in fiscal Q1 2025. A patient recieving cold therapy treatment using the company's products. Its net sales for the quarter grew 8% on a reported basis compared to the same quarter in 2024, while adjusted EBITDA reached $99 million, or 17.7% of sales. This translates to a 160 basis points growth compared to last year. The analyst attributed the growth to the company's successful commercial execution and integration efforts, as well as additional potential from cross-selling opportunities and new product launches. Enovis Corporation (NYSE:ENOV) is also increasing its free cash flow conversion and expanding margins, which positions it well for future profitability. The analyst further reasoned that the company has an attractive valuation and is trading below its peers, which points toward the potential for multiple expansions. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
29-04-2025
- Business
- Yahoo
Enovis Corporation (ENOV): Among Billionaire Mason Hawkins' Small-Cap Stocks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Enovis Corporation (NYSE:ENOV) stands against other billionaire Mason Hawkins' small-cap stocks with huge upside potential. Mason Hawkins is a prominent American investor, known for being the founder and chairman of Southeastern Asset Management. Hawkins holds a Bachelor of Arts in Finance from the University of Florida and later did his MBA in Finance from the University of Georgia. Before founding Southeastern Asset Management, the billionaire gained experience as a Director of Research at Atlantic National Bank and First Tennessee Investment Management. There he developed his value investment strategy and has since been known for his discipline in value investing. His fund Southeastern Asset Management also holds the same reputation, which can be witnessed through his concentrated portfolio of around 40 to 50 stocks. Southeastern Asset Management services 47 clients at the moment, with $5,271,901,660 as assets under management as of March 2024. Value investment is an investment strategy that employs buying stocks of well-managed and quality companies at prices significantly below their intrinsic value. The core of Hawkins' strategy is to purchase equities when their market price is no more than 60% of the firm's appraisal of their intrinsic value. Value investors believe that the market overreacts to economic news, which leads to movement in stock prices, however, this news does not affect the long-term fundamentals of a company. Therefore, investors like Mason Hawkins do not follow the herd and use financial research and analysis to find quality companies. Value investors are also known for holding companies for a long term, but also actively ferret out stock that the market is underestimating. Hawkins' disciplined and research-based investment strategy has earned him widespread recognition. He achieved Investor's Lifetime Achievement Award in 2005 and was also named Domestic Equity Fund Manager of the Year by Morningstar in 2006. Under the current market condition, Hawkins' value investment strategy has led Southeastern Asset Management's attention towards small-cap stocks. While the small-cap stocks have largely underperformed the market when compared to their large-cap counterparts. However, according to Francis Gannon, Co-Chief Investment Officer at Royce Investment Partners, small-caps are attractively priced for long-term investment opportunities. Gannon's investment advice aligns with Hawkins's strategy, as he suggests investing in quality small-cap companies with strong fundamentals, low debt, established long-term earnings, and significant upside potential. To compile the list of billionaire Mason Hawkins' 10 small-cap stocks with huge upside potential, we sifted through 13F filings of Southeastern Asset Management, from Insider Monkey. From these filings, we checked each stock's upside potential from CNN and ranked the stocks in ascending order of the upside potential. We have also added the stake Southeastern Asset Management holds in each company and the hedge fund sentiment around each stock. Please note that the data was recorded on April 28, 2025. Also note that for this article we have defined small-cap companies as those with a market capitalization between $1 billion to $10 billion. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Mason Hawkins of Southeastern Asset Management Enovis Corporation (NYSE:ENOV) is an international medical technology company that specializes in orthopedic solutions. Its core businesses include Prevention & Recovery solutions and Reconstructive solutions. The company mainly generates its revenue from designing and manufacturing medical technologies including orthopedic implants, bracing, supports, and surgical solutions. On April 3, Analyst Vik Chopra of Wells Fargo reiterated a Buy rating on the stock with a price target of $59. One of the key reasons behind the analyst's bullish sentiment is the appointment of the new CEO, Damien McDonald. The new CEO brings experience from his previous leadership roles in medical technology and orthopedic systems. Moreover, the analyst also noted that the company has reiterated its fiscal Q1 guidance reflecting a strong revenue and EBITDA. During fiscal 2024 the company achieved net sales of $2.1 billion, reflecting a 23% increase year-over-year. This was driven by exceptional growth in the Reconstructive segment with global revenues growing 59% during the same time. The Reconstructive segment benefited from a recent acquisition of Lima which helped enhance the product and technology portfolio. Enovis Corporation (NYSE:ENOV) is one of the best billionaire Mason Hawkins' 10 small-cap stocks with huge upside potential. Diamond Hill Small Cap Fund stated the following regarding Enovis Corporation (NYSE:ENOV) in its Q3 2024 investor letter: 'Other bottom Q3 contributors included Allient, Rimini Street and Enovis Corporation (NYSE:ENOV). Shares of innovative medical technology company Enovis underperformed amid investors' disappointment with its US surgical business growth, which slowed dramatically as the company focuses on integrating recent acquisition Lima. However, given the product overlap and different sales channels, we aren't surprised at these disruptions and believe the acquisition will prove beneficial in the long run.' Overall, OSCR ranks 1st on our list of billionaire Mason Hawkins' small-cap stocks with huge upside potential. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than OSCR but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
